CVAC - Can CureVac Win Market Share With Only 48% Vaccine Efficacy?
CureVac (NASDAQ: CVAC) surprised investors a few weeks ago when it announced disappointing data from a trial of its mRNA vaccine candidate. Many expected the German biotech would follow in the footsteps of fellow mRNA vaccine makers Pfizer and Moderna . These market leaders have reported efficacy of more than 90%.
After the CureVac report, it looked like company's dreams of a spot in the vaccine market were over -- at least in the near term. Then CureVac surprised investors a second time by saying it would move forward with a regulatory submission. Now, the big question is: If regulators authorize the candidate, can it win a spot in this competitive market?
Image source: Getty Images.
For further details see:
Can CureVac Win Market Share With Only 48% Vaccine Efficacy?